Designed Antibodies as Weapons against Infectious Diseases Jan Terje Andersen Department of Biosciences - University of Oslo Department of Immunology - Oslo University Hospital
Viruses 3 http://www.public-domain-image.com/free-imagesh ttp://phil.cdc.gov/phil/quicksearch.asp
Genetic material Protein coat Photo: Dan Higgins. ttp://phil.cdc.gov/phil/quicksearch.asp
The winter vomiting bug
The immune system
7
BUBBLE BOY DISEASE 8 Credit: Baylor College of Medicine Photo Archives
Antibiotics and anti-viral drugs
The Body’s Binding to intruder Foot Soldiers Binding to cells 10
Expanding use of therapeutic antibodies • The fastest growing class of bio-therapeutics • The global sale in 2014: >100 billion USD • Autoimmune diseases and cancer • Few against infectious diseases
12
Designed foot soldiers Site-specific Improved binding to modifications cell receptors
Killing of a virus in cell cultures 0% 50% 100% Natural antibody Designed antibodies
The soldiers are patrolling the blood
Superior lifespan of antibodies beyond that of natural antibodies Level in blood Designed antibodies Natural antibody Days after injection
• Patient compliance • Economy • Health system
Recommend Documents
Did you know a food allergy affects the immune system? ARMY OF WHITE BLOOD
Guideline on Biosimilar Monoclonal Antibodies Non-clinical issues A
Antibodies and Antigens Antibodies and Antigens Your body s natural defense
1 Bioventix Presentation: October 2019 Bioventix & antibodies for blood
1 Bioventix Presentation: March 2018 Bioventix & antibodies for blood
1 Bioventix Presentation: October 2018 Bioventix & antibodies for blood
1 Bioventix Presentation: April 2019 Bioventix & antibodies for blood
1 Bioventix Presentation: October 2017 Bioventix & antibodies for blood
Nuclear Weapons 2 Observations about Nuclear Weapons 1 Observations about
1 Bioventix Presentation: June 2016 Blood testing and antibodies Bioventix
Mologic partnering wit ith the In Institut Pasteur de Dakar Home of the
American Pharmacists Association Addressing the COVID-19 Crisis: An Open
NEWS RELEASE First Presentation of Early Data for Pembrolizumab (MK-3475),
New Treatment Options for Lupus Nephritis Brad H. Rovin, MD Professor of
Investor Presentation May 2019 1 Forward-Looking Statements This
Antibody-mediated therapy approaches in HIV-1 infection Florian Klein Arevir
J a n u a r y 20 1 8 SAB Team & Technology Together for 15+ Years
immunoYeast & The Antibody Discovery Toolkit Specific Antibodies on
Antibody Generation System Maturation, Selection and Production in CHO Cells
Production of Homogeneous ADCs with Combination Warheads and Bispecifics
STAY HOME | STAY HEALTHY | STAY CONNECTED | RETURN STRONGER STAY HOME. STAY
New CLSI Document for the Validation of Methods Preformed by Flow Cytometry